2 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow CADASIL: new trials by email Literature Review of CADASIL trials Research Report on CADASIL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Edaravone Dexborneol Sublingual Tablets for Blood-Brain Barrier Dysfunction in CADASIL Edaravone Dexborneol Sublingual Tablets - CADASIL | Phase 2 | Not yet recruiting | Huashan Hospital | 60 | 2026-07-01 | 2026-07-09 |
| CERebrolysin In CADASIL Cerebrolysin, 0.9 % NaCl - Cadasil | Phase 2 | Active not recruiting | Ever Neuro Pharma GmbH | 30 | 2023-11-29 | 2025-02-25 |
| Adrenomedullin for CADASIL Adrenomedullin - Cadasil | Phase 2 | Completed | National Cerebral and Cardiovascular Center, Japan | 60 | 2022-01-06 | 2023-10-10 |
| Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL Fremanezumab, Placebo - Cadasil, Migraine | Phase 2 | Withdrawn | Mayo Clinic | 2021-12-01 | 2022-02-28 | |
| Retina is a Marker for Cerebrovascular Heath Cilostazol - Cerebral Small Vessel Diseases, Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 100 | 2021-02-09 | 2026-08-03 |
| Efficacy and Safety of Tocotrienols in CADASIL HOV-12020 (Palm tocotrienols complex), Placebo - Cadasil | Phase 2 | Completed | Hovid Berhad | 50 | 2020-12-21 | 2026-02-02 |
| Safety Study of Dabigatran in CADASIL Dabigatran, Antiplatelets - CADASIL | Phase 2 | Unknown | S. Andrea Hospital | 50 | 2011-06-01 | 2014-02-11 |
Cerebral Small Vessel Diseases (2) · Cerebrovascular Disorders (1) · Cognitive Dysfunction (1) · Dementia (1) · Migraine Disorders (1) · Stroke (1)
Brain Diseases (7) · Brain Infarction (7) · Brain Ischemia (7) · Cardiovascular Diseases (7) · Central Nervous System Diseases (7) · Cerebral Arterial Diseases (7) · Cerebral Infarction (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Dementia, Vascular (7) · Genetic Diseases, Inborn (7) · Infarction (7) · Intracranial Arterial Diseases (7) · Ischemia (7) · Necrosis (7) · Nervous System Diseases (7)
Adrenomedullin (1) · Cilostazol (1) · Dabigatran (1) · Sodium Chloride (1) · Tocotrienols (1) · cerebrolysin (1) · erenumab (1) · fremanezumab (1)
Mayo Clinic (2) · Ever Neuro Pharma GmbH (1) · Hovid Berhad (1) · Huashan Hospital (1) · National Cerebral and Cardiovascular Center, Japan (1) · S. Andrea Hospital (1)
China (1) · Czechia (1) · France (1) · Italy (1) · Japan (1) · United States (1)
David Ho (1) · Francesco Orzi, MD (1) · James F Meschia (1) · Michelle P Lin, MD, MPH (1) · Pr Hugues Chabriat (1)